Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myeloma

Hamza Hashmi • 10 Dec 2022
ASH 2022
Multiple Myeloma CAR-T

Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, explains where BCMA-targeted CAR-T therapy may fit in the treatment regimen of standard-risk and high-risk multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Sanofi: Consultancy, Speakers Bureau; GSK: Speakers Bureau; KARYOPHARM: Speakers Bureau; JANSSEN: Consultancy; BMS: Consultancy.

More from Hamza Hashmi

1:45
Using frailty to determine CAR-T eligibility in patients with R/R multiple myeloma
Hamza Hashmi • 10 Dec 2023
1:43
Real-world outcomes of teclistamab for R/R multiple myeloma
Hamza Hashmi • 10 Dec 2023
1:21
Factors associated with early progression after ide-cel in patients with R/R multiple myeloma
Hamza Hashmi • 10 Dec 2022
1:37
DPd against DVd for daratumumab-naïve patients with R/R multiple myeloma
Hamza Hashmi • 10 Dec 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals